SCHEDULE 13D/A: Major Shareholder Reduces Stake in Yubo International Biotech Ltd

Chinaone Technology Limited and its controlling person, Yang Wang, have significantly reduced their beneficial ownership in Yubo International Biotech Ltd by selling 2 million shares of Class A Common Stock.

Summary

• Chinaone Technology Limited and Yang Wang, collectively the Reporting Persons, filed Amendment No. 1 to their Schedule 13D.
• The amendment reports a reduction in their beneficial ownership of Yubo International Biotech Ltd's Class A Common Stock.
• On July 15, 2024, the Reporting Persons sold 2,000,000 shares of Class A Common Stock at a price of $0.12 per share.
• This transaction was conducted in the open market through a broker.
• The sale resulted in a decrease of over 1% in their aggregate percentage ownership.
• Following the transaction, the Reporting Persons beneficially own 17,211,400 shares, representing 14.4% of the Class A Common Stock outstanding.
• The percentage is based on 119,816,343 shares of Class A Common Stock outstanding as of March 31, 2025, as disclosed in the Issuer's Annual Report on Form 10-K.

Sentiment

Score: 3

Explanation: The document reports a significant reduction in beneficial ownership by a major shareholder, which is generally perceived negatively by the market as it could signal a lack of confidence or a need for liquidity from the selling party. The low sale price of $0.12 per share further contributes to a negative sentiment.

Negatives

• A significant shareholder, Chinaone Technology Limited and its controlling person Yang Wang, reduced their stake by 2,000,000 shares.
• The sale price of $0.12 per share indicates a low valuation for the shares sold.
• The reduction in ownership by over 1% could be perceived negatively by the market, signaling a lack of confidence or a need for liquidity from the Reporting Persons.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future operations or financial performance.

Industry Context

This filing is a routine disclosure of a change in beneficial ownership by a significant shareholder. Without further context on Yubo International Biotech Ltd's specific industry (biotech, as implied by name), it's difficult to assess broader industry trends. However, a major shareholder reducing their stake can sometimes signal internal perspectives on future company performance or liquidity needs, which could be a point of concern for investors in the biotech sector, known for its capital intensity and long development cycles.

Stakeholder Impact

• Shareholders: The reduction in stake by a major shareholder could lead to negative market sentiment and potentially impact share price due to perceived lack of confidence or increased supply of shares.
• Company Management: May need to address market concerns regarding the major shareholder's divestment.

Key Dates

Recommendation

Keywords

Yubo International Biotech Ltd, Chinaone Technology Limited, Yang Wang, Schedule 13D/A, beneficial ownership, share sale, Class A Common Stock, SEC filing, shareholder stake, biotech